Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K.

J Immunother Cancer. 2019 Jul 10;7(1):172. doi: 10.1186/s40425-019-0643-8.

2.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K.

Clin Cancer Res. 2016 Jan 15;22(2):426-35. doi: 10.1158/1078-0432.CCR-15-0620. Epub 2015 Sep 4.

3.

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Ayeni D, Politi K, Goldberg SB.

Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13.

4.

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

Politi K, Ayeni D, Lynch T.

Cancer Cell. 2015 Jun 8;27(6):751-3. doi: 10.1016/j.ccell.2015.05.012.

5.

Julia-Kocienski Approach to Trifluoromethyl-Substituted Alkenes1.

Ayeni DO, Mandal SK, Zajc B.

Tetrahedron Lett. 2013 Nov 6;54(45):6008-6011.

6.

Femorofemoral bypass: a valuable procedure.

Salerno TA, Ayeni DR, Blundell PE, Chiu RC.

Can J Surg. 1978 Mar;21(2):112-3.

PMID:
630461

Supplemental Content

Support Center